febuxostat Side Effects
Also known as: Uloric
Analysis of 16,005 adverse event reports submitted to the FDA from 2009 to 2025.
Total Reports
16,005
Death-Related
2,099
13.1% of reports
Hospitalizations
6,835
42.7% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 2,099 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 512 |
| PNEUMONIA | 166 |
| CARDIAC FAILURE | 134 |
| ACUTE KIDNEY INJURY | 128 |
| DYSPNOEA | 120 |
| PYREXIA | 114 |
| OFF LABEL USE | 112 |
| RESPIRATORY FAILURE | 102 |
| SEPSIS | 102 |
| RENAL FAILURE | 96 |
| ANAEMIA | 91 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 82 |
| PLATELET COUNT DECREASED | 81 |
| MALAISE | 77 |
| DIARRHOEA | 76 |
| CHRONIC KIDNEY DISEASE | 75 |
| DECREASED APPETITE | 75 |
| FEBRILE NEUTROPENIA | 75 |
| CARDIAC FAILURE CONGESTIVE | 64 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 61 |
Reactions in Hospitalization Reports
Top reactions in 6,835 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| ACUTE KIDNEY INJURY | 555 |
| DIARRHOEA | 429 |
| ANAEMIA | 413 |
| PNEUMONIA | 411 |
| NAUSEA | 395 |
| OFF LABEL USE | 395 |
| DYSPNOEA | 393 |
| PYREXIA | 346 |
| RASH | 319 |
| FATIGUE | 311 |
| CARDIAC FAILURE | 306 |
| DECREASED APPETITE | 305 |
| HEADACHE | 296 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 275 |
| RENAL IMPAIRMENT | 270 |
| FALL | 262 |
| DRUG INEFFECTIVE | 258 |
| PAIN | 241 |
| ERYTHEMA | 237 |
| MALAISE | 237 |
Nearby — Related Medications
What the FAERS Data Reveals About febuxostat Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 16,005 voluntary reports linked to febuxostat and its brand equivalents (Uloric), spanning 2009 through 2025. Of those, 2,099 (13.1%) listed death as an outcome and 6,835 (42.7%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 32% were female and 67% male; age distribution skews toward 75+, with 3,919 reports in that bracket. The single most reported reaction is diarrhoea with 849 submissions, followed by nausea and acute kidney injury.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.